HLA‐DRB1*16‐restricted recognition of myeloid cells, including CD34+ CML progenitor cells

No abstract is available for this paper.

• Publication year

  2003

• Venue

  British Journal of Haematology

• Publication date

  2003-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1046/j.1365-2141.2003.04341.xPMID 12780786
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease

  2001cited by this paper
• Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.

  2001cited by this paper
• UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition.

  2000cited by this paper
• DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection.

  2000cited by this paper
• Increasing mixed haematopoietic chimaerism after BMT with total depletion of CD4+ and partial depletion of CD8+ lymphocytes is associated with a higher incidence of relapse

  1999cited by this paper
• Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes.

  1999cited by this paper
• Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34(+) cells.

  1998cited by this paper
• Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution.

  1998cited by this paper
• T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation.

  1998cited by this paper
• Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.

  1998cited by this paper
• CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens.

  1998cited by this paper
• Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.

  1998cited by this paper
• Much ado about minor histocompatibility antigens.

  1998cited by this paper
• The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism.

  1998cited by this paper
• A method for the production of CD4+ chronic myelogenous leukemia-specific allogeneic T lymphocytes.

  1997cited by this paper
• Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.

  1997cited by this paper
• Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL.

  1997cited by this paper
• Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation.

  1997cited by this paper
• Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy

  1997influential reference
• A CASP-8 Mutation Recognized by Cytolytic T Lymphocytes on a Human Head and Neck Carcinoma

  1997cited by this paper
• Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect

  1997cited by this paper
• HLA class II restricted T-cell reactivity to a developmentally regulated antigen shared by leukemic cells and CD34+ early progenitor cells.

  1997cited by this paper
• A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N- acetylglucosaminyltransferase V gene

  1996cited by this paper
• Graft-versus-myeloma effect: proof of principle.

  1996cited by this paper
• Graft-versus-myeloma effect in two cases.

  1996cited by this paper
• Human T-cell receptor variable gene segment families

  1995cited by this paper
• Allorecognition and graft-versus-host disease.

  1995cited by this paper
• Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.

  1995cited by this paper
• Identification of a graft versus host disease-associated human minor histocompatibility antigen.

  1995cited by this paper
• Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity.

  1995cited by this paper
• Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.

  1995cited by this paper
• Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein.

  1995cited by this paper
• Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes.

  1995cited by this paper
• Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.

  1994cited by this paper
• Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse.

  1994cited by this paper
• Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones.

  1994cited by this paper
• Complete remission following donor leukocyte infusion in ALL relapsing after haploidentical bone marrow transplantation.

  1994cited by this paper
• Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT.

  1993cited by this paper
• Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation.

  1993cited by this paper
• The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

  1993cited by this paper
• Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose.

  1993cited by this paper
• Reinduction of remission of chronic myeloid leukemia by donor leukocyte transfusion following relapse after bone marrow transplantation: recovery complicated by initial pancytopenia and late dermatomyositis.

  1993cited by this paper
• T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia.

  1993cited by this paper
• Interleukin-2, interferon-gamma and natural killer cell activity in bronchoalveolar lavage fluid from marrow transplant recipients with cytomegalovirus pneumonia.

  1993cited by this paper
• Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow.

  1993cited by this paper
• Tissue distribution of human minor Histocompatibility antigen. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human CTLs defined non-MHC antigens.

  1992cited by this paper
• Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens.

  1992cited by this paper
• Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression.

  1992cited by this paper
• Molecular remission occurring after donor leukocyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.

  1992cited by this paper
• Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes

  1991cited by this paper
• Identification of classical minor histocompatibility antigen as cell-derived peptide

  1990cited by this paper
• Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.

  1990cited by this paper
• Immunodominance in the graft-vs-host disease T cell response to minor histocompatibility antigens.

  1990cited by this paper
• Organization and sequences of the diversity, joining, and constant region genes of the human T-cell receptor beta chain.

  1985cited by this paper
• Primary in vitro generation of cytotoxic cells specific for human minor histocompatibility antigens between HLA-identical siblings.

  1984cited by this paper

• HLA risk markers for chronic myelogenous leukemia in Eastern Canada

  2009cites this paper
• Identification of a 40S Ribosomal Protein S4–Derived H-Y Epitope Able to Elicit a Lymphoblast-Specific Cytotoxic T Lymphocyte Response

  2005cites this paper
• B-cell expansion in the presence of the novel 293-CD40L-sCD40L cell line allows the generation of large numbers of efficient xenoantigen-free APC.

  2005cites this paper
• UTY‐specific TCR‐transfer generates potential graft‐versus‐leukaemia effector T cells

  2005cites this paper